secwatch.observer — SEC 8-K summary
======================================

Issuer:     SAB Biotherapeutics, Inc. (SABS)
CIK:        0001833214
Form:       8-K
Filed at:   2023-07-03T23:59:59+00:00
Accession:  0001437749-23-019198
Event type: other_material
Sentiment:  neutral
Materiality: 0.15
Item codes: 5.07
LLM model:  deepseek-v4-flash:cloud@v2

SAB Biotherapeutics shareholders elect Spragens and Link as Class II directors, ratify auditor
--------------------------------------------------------------------------------

- Shareholders elected Jeffrey G. Spragens and David Link as Class II directors for three-year terms expiring at 2026 annual meeting.
- Appointment of Mayer Hoffman McCann P.C. as independent auditor for FY 2023 ratified with 37.25M votes for, 33K against.
- Over 37.5M shares voted, representing 74.45% of outstanding shares, constituting a quorum.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1833214/000143774923019198/0001437749-23-019198-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1833214/000143774923019198/sabs20230629c_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-23-019198

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer